<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02049866</url>
  </required_header>
  <id_info>
    <org_study_id>AAAN0161</org_study_id>
    <secondary_id>1R01FD005114-01A2</secondary_id>
    <nct_id>NCT02049866</nct_id>
  </id_info>
  <brief_title>Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP</brief_title>
  <official_title>Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis: a Phase IIB Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elizabeth Shane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Creighton University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate antiresorptive therapy with denosumab
      (Prolia) for prevention of bone loss after stopping teriparatide (TPTD) in premenopausal
      women with idiopathic osteoporosis.

      Premenopausal women who have received TPTD in the FDA Orphan Diseases Program-funded trial,
      &quot;A Phase 2 Study of Teriparatide for the Treatment of Idiopathic Osteoporosis in
      Premenopausal Women&quot; (NCT01440803) may be eligible to participate in the current study, a
      36-month open-label pilot study of denosumab (ProliaÂ®, 60mg SC every 6 months).

      The goals of the study are to estimate the effects of denosumab on central and peripheral, as
      well as trabecular and cortical, bone mass and microstructure and to obtain preliminary data
      to inform the design of a future randomized study. This study presents the first opportunity
      to study the effects of denosumab after TPTD in this unique and severely affected group of
      young women.

      Funding Source - FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis in premenopausal women with normal menstrual function and no specific cause is
      termed idiopathic osteoporosis (IOP). IOP is a rare disease with an estimated prevalence of
      &lt;200,000 affected premenopausal women in the United States.

      Denosumab, a potent inhibitor of osteoclast-mediated bone resorption, leads to continuous
      gains in both trabecular and cortical bone mineral density (BMD). Moreover, denosumab is not
      retained in the skeleton, and may thus be preferable for use in young women who may be
      contemplating future pregnancies. The investigators hypothesize that denosumab, initiated
      after completion of two years of TPTD, will maintain or improve central and peripheral areal
      and volumetric BMD, microstructure and stiffness in premenopausal women with IOP.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2014</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in lumbar spine areal BMD by DXA</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Adult Idiopathic Generalized Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia</other_name>
    <other_name>Xgeva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women completing NCT01440803 who remain without a disease or medication that
             causes osteoporosis will be offered enrollment into this study.

          -  (Premenopausal status is no longer be required for entry.)

        Exclusion Criteria:

          -  Renal insufficiency or liver disease: Creatinine, transaminase (AST)/alanine
             transaminase (ALT) above upper limit of normal

          -  Vitamin D deficiency: 25-hydroxyvitamin D (25-OHD) &lt;30 ng/mL

          -  Pregnancy: urine pregnancy test must be negative
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adi Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Bucovsky, BA</last_name>
    <phone>212-305-7225</phone>
    <email>mb3523@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adi Cohen, MD</last_name>
    <phone>212-342-1291</phone>
    <email>ac1044@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Creighton University</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-280-4470</phone>
    </contact>
    <investigator>
      <last_name>Robert Recker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joan Lappe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-305-7225</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Shane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adi Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://columbiamedicine.org/divisions/Endo/index.shtml</url>
    <description>Columbia University, Dept of Medicine, Division of Endocrinology website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>January 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2014</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>premenopausal</keyword>
  <keyword>denosumab</keyword>
  <keyword>idiopathic</keyword>
  <keyword>Idiopathic Osteoporosis in Premenopausal Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

